ArticleCase reports in pediatrics2025
Failure of GLP-1 Agonist Therapy to Improve Weight in a 3-Year-Old Patient With Tumor-Related Obesity.
Article in Case reports in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Obesity medications and acquired hypothalamic obesity in adults: A two-case experience.Obesity pillars · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 19-month-old female patient presented due to rapid weight gain starting at age 5 months. Due to continued abnormal weight gain after 1 year of age, an MRI of the brain was performed, revealing a 5.5 × 2.6 × 2.3 cm mass centered within the medulla oblongata with extension to the C3 vertebral body. Biopsy confirmed a diagnosis of ganglioglioma. A trial of topiramate was attempted, but there was no improvement in weight gain after 2 months. The patient started on 0.3 mg liraglutide daily, and the dose was titrated up to 3 mg daily over 3 months. The patient did not experience abdominal pain, nausea, vomiting, or diarrhea. Weight continued to increase at a drastic rate, and increased appetite persisted. Liraglutide was discontinued. Liraglutide may be safe for use in children as young as age 3 years. However, its effect on weight loss in cases of hypothalamic obesity may be limited. The medulla oblongata contains GLP-1 receptors and is involved in the suppression of food intake. In the presented case, lack of response to treatment was likely due to medullary damage from the tumor. Further research about the etiology of neurogenic causes of obesity is needed so targeted therapies may be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.